1. Home
  2. PRFX vs CMND Comparison

PRFX vs CMND Comparison

Compare PRFX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.89

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$2.41

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRFX
CMND
Founded
2007
2017
Country
Israel
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRFX
CMND
Price
$0.89
$2.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
95.3K
209.0K
Earning Date
02-27-2026
01-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$1.74
52 Week High
$6.65
$64.80

Technical Indicators

Market Signals
Indicator
PRFX
CMND
Relative Strength Index (RSI) 49.84 64.91
Support Level $0.66 $2.36
Resistance Level $0.74 $2.74
Average True Range (ATR) 0.06 0.22
MACD 0.01 -0.01
Stochastic Oscillator 74.46 66.42

Price Performance

Historical Comparison
PRFX
CMND

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Share on Social Networks: